中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 新药研究国家重点实验室
Repurposing of Rutan showed effective treatment for COVID-19 disease

文献类型：期刊论文

作者Salikhov, Shavkat I.7; Abdurakhmonov, Ibrokhim Y.6; Oshchepkova, Yuliya I.7; Ziyavitdinov, Jamolitdin F.7; Berdiev, Nodir Sh.7; Aisa, Haji Akber5; Shen, Jingshan4; Xu, Yechun4; Xu, H. Eric4; Jiang, Xiangrui4
刊名FRONTIERS IN MEDICINE
出版日期2023-11-29
卷号10页码:13
关键词COVID-19 SARS-CoV-2 3CLpro RdRp Rhus coriaria Rutan clinical trial
DOI10.3389/fmed.2023.1310129
通讯作者Abdurakhmonov, Ibrokhim Y.(i.y.abddurakhmonov@gmail.com)
英文摘要Previously, from the tannic sumac plant (Rhus coriaria), we developed the Rutan 25 mg oral drug tablets with antiviral activity against influenza A and B viruses, adenoviruses, paramyxoviruses, herpes virus, and cytomegalovirus. Here, our re-purposing study demonstrated that Rutan at 25, 50, and 100 mg/kg provided a very effective and safe treatment for COVID-19 infection, simultaneously inhibiting two vital enzyme systems of the SARS-CoV-2 virus: 3C-like proteinase (3CLpro) and RNA-dependent RNA polymerase (RdRp). There was no drug accumulation in experimental animals' organs and tissues. A clinical study demonstrated a statistically significant decrease in the C-reactive protein and a reduction of the viremia period. In patients receiving Rutan 25 mg (children) and 100 mg (adults), the frequency of post-COVID-19 manifestations was significantly less than in the control groups not treated with Rutan tablets. Rutan, having antiviral activity, can provide safe treatment and prevention of COVID-19 in adults and children.Clinical Trial Registration ClinicalTrials.gov, ID NCT05862883.
WOS关键词DEPENDENT RNA-POLYMERASE ; SARS-COV-2 ; INHIBITORS ; SAFETY ; FAVIPIRAVIR
资助项目Ministry of the Innovative Development Republic of Uzbekistan ; State Center for the examination and standardization of medicines, medical products, and medical equipment of the Ministry of Health of the Republic of Uzbekistan
WOS研究方向General & Internal Medicine
语种英语
出版者FRONTIERS MEDIA SA
WOS记录号WOS:001124320200001
源URL[http://119.78.100.183/handle/2S10ELR8/308287]  
专题新药研究国家重点实验室
通讯作者Abdurakhmonov, Ibrokhim Y.
作者单位1.Ctr Dev Profess Qualificat Med Workers, Tashkent, Uzbekistan
2.Minist Hlth Uzbekistan, Dept Hepatol, Sci Res Inst Virol, Tashkent, Uzbekistan
3.Chinese Acad Sci, Wuhan Inst Virol, Wuhan, Peoples R China
4.Chinese Acad Sci, State Key Lab Drug Res, CAS Key Lab Receptor Res, Shanghai Inst Mat Med, Shanghai, Peoples R China
5.Chinese Acad Sci, Xinjiang Tech Inst Phys & Chem, Urumqi, Peoples R China
6.Acad Sci Republ Uzbekistan UzAS, Ctr Genom & Bioinformat, Tashkent, Uzbekistan
7.AS Sadykov Inst Bioorgan Chem UzAS, Tashkent, Uzbekistan
推荐引用方式
GB/T 7714		 Salikhov, Shavkat I.,Abdurakhmonov, Ibrokhim Y.,Oshchepkova, Yuliya I.,et al. Repurposing of Rutan showed effective treatment for COVID-19 disease[J]. FRONTIERS IN MEDICINE,2023,10:13.
APA Salikhov, Shavkat I..,Abdurakhmonov, Ibrokhim Y..,Oshchepkova, Yuliya I..,Ziyavitdinov, Jamolitdin F..,Berdiev, Nodir Sh..,...&Lokteva, Lyubov M..(2023).Repurposing of Rutan showed effective treatment for COVID-19 disease.FRONTIERS IN MEDICINE,10,13.
MLA Salikhov, Shavkat I.,et al."Repurposing of Rutan showed effective treatment for COVID-19 disease".FRONTIERS IN MEDICINE 10(2023):13.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。